TR-002 for Advanced Cancer
Phase 1
52
about 4.3 years
18+
1 site in CA
What this study is about
This trial is testing the safety and side effects of TR-002 in people with advanced, unresectable or metastatic solid tumors and unresectable or metastatic, refractory pancreatic adenocarcinoma. The goal is to determine the best dose of TR-002 that can be safely used in this type of cancer treatment.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take TR-002
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Incidence of dose limiting toxicity (DLTs), Number of participants experiencing treatment-related adverse events
Secondary: Apparent clearance/bioavailability, Half-life, Objective response rate (ORR), Overall survival, Peak Plasma Concentration (Cmax), Progression free survival
Oncology